Flamingo announces agreement with CUA Health
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Flamingo AI Limited (ASX:FGO) informed the market this morning that it has signed a binding commercial term sheet with CUA Health Ltd, a subsidiary of Credit Union Australia, for a paid trial of FGO’s Cognitive Virtual Sales Assistant ROSIE.
During the three months spanning the live evaluation trial, CUA’s customers as well as CUA Health members will interact with ROSIE in a similar arrangement to FGO’s pre-existing live evaluation trials with Australian companies DirectMoney and AMP.
Flamingo’s CEO, Dr Catriona Wallace, commented on today’s announcement.
“We are extremely pleased to be working with CUA Health on the deployment of a Virtual Assistant to support their customers purchasing Health Insurance.
“We believe that AI and Machine Learning technology such as Flamingo provides will be very relevant to the health insurance sector,” she said.
National Sales & Marketing Manager at CUA Health, Richard Martin said, “This is an exciting collaboration opportunity that has arisen from our sponsorship of the Stone & Chalk fintech hub.
“We’re keen to test what opportunities there are for this technology to supplement our personalised interactions with members, potentially managing many of the most common health insurance inquiries coming in through our digital sales channels.”
It should be noted that it is early stages in this partnership and investors should seek professional financial advice for further information if considering this stock for their portfolio.
Earlier this week, the company released an update regarding live evaluation trials of ROSIE currently underway with three of FGO’s clients in the US and Australia.
It also reported that feedback from client companies has so far has been highly positive, and the company is in discussions with several clients relating to a shift from live evaluation to Monthly Recurring Revenue arrangements.
FGO continues to build its strong sales pipeline across all three regions. It continues its supportive partnership with the US-based Clarion Group, which has historically been an excellent source of sale and contract leads for FGO.
Wallace conducted several sales meetings with Clarion representatives during a trip to the US this month, with the company also announcing it would be expanding its sales teams in both the US and Asia Pacific.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.